Meropenem Dosing Recommendations in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy
Nephrology · 2026-04 · 31 (4)
DOI: 10.1111/nep.70196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, online erschienen am 30.03.2026. Verfasst von Jirapat Vamananda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Intermittent Renal Replacement Therapy. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Chulalongkorn University.
Abstract (Originalsprache)
Aim
Meropenem dosing regimens in critically ill patients undergoing prolonged intermittent renal replacement therapy (PIRRT) are limited. This study aimed to evaluate the probability of target attainment (PTA) of various meropenem regimens in these patients receiving PIRRT, using Monte Carlo simulations (MCS).
Methods
Mathematical models were developed using published pharmacokinetic (PK) data from critically ill patients. Simulations incorporated PIRRT modalities (haemodialysis [HD] and hemofiltration [HF]) with an effluent rate of 300 mL/min and various durations of 4, 6, 8, or 10 h. MCS assessed drug exposure over 48 h in 10 000 virtual patients per regimen. The pharmacodynamic (PD) targets were free drug concentrations that remained above 4 times the minimum inhibitory concentration (MIC) of 2 mg/L. Optimal regimens were those achieving ≥ 90% PTA in each PIRRT setting.
Results
In alternate‐day PIRRT, most session durations use a 1000 mg loading dose followed by 500 mg every 8 h, except for 10‐h HD, which requires 1000 mg every 12 h. In daily PIRRT, HD requires 750 mg every 8 h for 4–8‐h sessions and 1000 mg every 8 h for 10‐h sessions. For HF, recommended regimens range from a 1000 mg loading dose followed by 500 mg every 8 h for 4‐h sessions to 1000 mg every 12 h for 6–8‐h sessions and 750 mg every 8 h for 10‐h sessions.
Conclusion
Optimized daily meropenem doses of 2000–3000 mg for PIRRT are recommended to ensure safe and effective outcomes, though further clinical validation is needed before widespread use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Pharmacometrics for Health Sciences Research Group, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Faculty of Pharmacy, Siam University, Bangkok, Thailand.
- Department of Clinical and Administrative Pharmacy Sciences, Howard University, College of Pharmacy, Washington, D.C., USA.
- Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand.
- School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
ORCID-Profile: Weerachai Chaijamorn, Dhakrit Rungkitwattanakul
Förderung
- Chulalongkorn University
Zitieren
APA
Vamananda, J., Chaijamorn, W., Charoensareerat, T., Rungkitwattanakul, D., Pattharachayakul, S., Boonpeng, A., Sriboonruang, T., & Srisawat, N. (2026). Meropenem Dosing Recommendations in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Nephrology, 31(4). https://doi.org/10.1111/nep.70196
Vancouver
Vamananda J, Chaijamorn W, Charoensareerat T, Rungkitwattanakul D, Pattharachayakul S, Boonpeng A, et al. Meropenem Dosing Recommendations in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Nephrology. 2026;31(4). doi:10.1111/nep.70196
BibTeX
@article{Vamananda2026,
author = {Vamananda, Jirapat and Chaijamorn, Weerachai and Charoensareerat, Taniya and Rungkitwattanakul, Dhakrit and Pattharachayakul, Sutthiporn and Boonpeng, Apinya and Sriboonruang, Tatta and Srisawat, Nattachai},
title = {Meropenem Dosing Recommendations in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy},
journal = {Nephrology},
year = {2026},
volume = {31},
number = {4},
doi = {10.1111/nep.70196}
}
EUVIMED